Report On TherapeuticsMD Inc.’s (TXMD) Price Performance

The stock of TherapeuticsMD Inc. (NASDAQ:TXMD) decreased by remained unchanged at $0.77, down -2.67 percent. The last five days have seen an average of 3,299,720 shares of common stock traded. 13 times new highs were reached in the current year, with a fall of -$0.4432. The average number of shares traded over the last 20 days was 3,235,565, while the average volume over the last 50 days totaled 5,168,996.

TXMD stock appreciated 7.09% since last month. On 10/11/21, the company’s shares reached a one-month low of $0.6891. The stock touched a high of $2.75 on 02/09/21, after rallying from a low of $0.67 in 52 weeks. The price of TXMD stock has declined by -36.63% or -$0.4432 this year, reaching a new high 13 times. Still, the stock price is down -72.12% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

There have been 68 days since TherapeuticsMD Inc. (TXMD) last reported insider trading activity on Aug 18. On Aug 18, Director Collins Cooper C. acquired 900,000 shares at $0.72 each. This transaction resulted in the insider spending $648,000. On Aug 17, Collins Cooper C. added 100,000 shares at a price of US$0.77. After the transaction, the insider now owns 336,864 shares. Director Ling Karen had earlier bought 33,445 shares on Aug 17 for $0.75 a share. The transaction was completed for $25,084.

For the three months ended June 29, TherapeuticsMD Inc.’s quick ratio was 2.00, while its current ratio was 2.10, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 79.10% percent. Based on annual data, it had gross profit of $48.9 million and revenue of $64.87 million.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TXMD’s return on assets (ROA) during the last 12 months has been -77.50%. There was a -136.80% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 210.00%.

Earnings Surprise

According to TherapeuticsMD Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $23.0 million, while revenues rose by 53.48% to $19.87 million. It was predicted that TherapeuticsMD Inc.’s quarterly earnings would be -$0.11, but it ended up being -$0.11. EBITDA was -$35.41 million for the quarter. At the end of TherapeuticsMD Inc.’s most recent quarter ended June 29, its liabilities totaled 259.68 million, while its total debt was $193.64 million. Equity owned by shareholders amounts to $423.82 million.

Technical Picture

Here’s a quick look at TherapeuticsMD Inc.’s (TXMD) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 56.69%, suggesting the stock is Neutral, with a 45.01% historical volatility rate.

The stochastic %K and %D were 72.34% and 79.61% respectively, while the average true range (ATR) was 0.0375. Based on the 14-day stochastic reading of 60.28%, the RSI (14) reading is 53.38%. On the 9-day MACD Oscillator, the stock is at 0.0263, and the 14-day reading is at 0.0445.

Analyst Ratings

TherapeuticsMD Inc. (NASDAQ: TXMD) was downgraded by Jefferies to a an Underperform rating in its latest research report. The stock was previously rated as a a Hold. Analysts have assigned TherapeuticsMD Inc. (TXMD) an Buy rating. TXMD is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.

What is TXMD’s price target for the next 12 months?

The current consensus forecast for the stock is between $4.00 and $5.00, with a median target price of $5.00. In analyzing these forecasts, the average price target given by analysts for TherapeuticsMD Inc. (TXMD) is $4.75.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam